SCH 48461

Known as: SCH-48461 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2004
012319952004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
beta-Lactams have recently been identified as potent, highly efficacious cholesterol absorption inhibitors (CAIs). The discovery… (More)
Is this relevant?
2002
2002
Intestinal cholesterol absorption is a major determinant of plasma low density lipoprotein-cholesterol (LDL-C) concentrations… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2002
2002
The discoveries of Sch 48461 and Sch 58235 and their novel pharmacology of inhibition of cholesterol absorption have prompted… (More)
Is this relevant?
2001
2001
SCH 48461, an inhibitor of gastrointestinal absorption of cholesterol, was evaluated for its effects on lipid parameters in… (More)
Is this relevant?
2001
2001
Ezetimibe (SCH 58235) and SCH 48461 are potent cholesterol absorption inhibitors, which cause significant decreases in plasma… (More)
Is this relevant?
2001
2001
A direct liquid chromatography method was developed for the diastereo- and enantioselective analysis of a C3,C4-substituted beta… (More)
Is this relevant?
1996
1996
A series of azetidinone cholesterol absorption inhibitors related to SCH 48461 ((-)-6) has been prepared, and compounds were… (More)
Is this relevant?
1995
1995
The amount of cholesterol that circulates in the plasma as lipoproteins can be affected by the balance of cholesterol metabolism… (More)
Is this relevant?